Pratt G, Bowcock S, Lai M, Bell S, Bird J, D'Sa S, Cavenagh J, Cook G, Morgan G, Owen R, Snowden J A, Yong K, Davies F
Haematology, Heart of England NHS Trust, Institute for Cancer Studies, University of Birmingham, Birmingham, UK.
Haematology, South London Healthcare NHS Trust, Haematology Kent, Kent, UK.
Int J Lab Hematol. 2014 Feb;36(1):20-8. doi: 10.1111/ijlh.12097. Epub 2013 Apr 25.
Bendamustine is a unique bifunctional alkylating agent with promising activity in myeloma. Despite the increasing number of studies demonstrating its efficacy in both the upfront and relapse settings, including patients with renal insufficiency, the optimal use of bendamustine, in terms of dosage, schedule and combination with other agents, has yet to be defined. It is currently licensed for use as frontline treatment with prednisolone for patients with myeloma who are unsuitable for transplantation and who are contraindicated for thalidomide and bortezomib. Studies in relapsed/refractory patients are currently ongoing with other combinations. Given the increasing data to date, the UK Myeloma Forum believes that bendamustine with steroids alone or in combination with a novel agent could be considered for patients with multiply relapsed myeloma. This document provides guidance for the use of bendamustine for patients with myeloma until the results of definitive studies are available.
苯达莫司汀是一种独特的双功能烷化剂，在骨髓瘤治疗中具有良好的活性。尽管越来越多的研究表明其在初始治疗和复发治疗中均有效，包括对肾功能不全的患者，但在剂量、给药方案以及与其他药物联合使用方面，苯达莫司汀的最佳使用方式尚未明确。目前，它已被批准与泼尼松龙联合用于不适宜移植且对沙利度胺和硼替佐米禁忌的骨髓瘤患者的一线治疗。目前正在对复发/难治性患者进行其他联合用药的研究。鉴于目前已有越来越多的数据，英国骨髓瘤论坛认为，对于多次复发的骨髓瘤患者，可考虑单独使用苯达莫司汀联合类固醇或与新型药物联合使用。在确定性研究结果出来之前，本文档为骨髓瘤患者使用苯达莫司汀提供指导。
